recent
pharmacophor
gener
four
fda
approv
compound
diseas
nonantivir
result
two
high
throughput
screen
ebola
viru
close
match
receptorligand
pharmacophor
ebola
viral
protein
followup
dock
studi
suggest
compound
may
favor
inhibitori
interact
receptor
cofactor
rna
polymeras
transcript
complex
help
viru
evad
immun
respons
block
activ
interferon
regulatori
factor
requir
induct
interferon
alpha
beta
thu
block
allow
enhanc
host
immun
respons
ebola
viru
propos
similar
compound
may
act
via
close
relat
mechan
though
experiment
evid
directli
prove
yet
anoth
recent
studi
highlight
abil
three
clinic
approv
ion
channel
blocker
inhibit
ebola
viru
cellular
entri
drug
amiodaron
dronedaron
verapamil
given
concentr
possibl
human
serum
effect
number
filovirus
author
hypothes
drug
may
act
disrupt
late
endosom
process
disrupt
calcium
signal
requir
viral
entri
cours
none
aforement
fda
approv
drug
design
target
ebola
viru
amodiaquin
chloroquin
antimalari
clomiphen
toremifen
select
estrogen
receptor
modul
amiodaron
dronedaron
verapamil
antiarrhythm
interestingli
compound
common
tertiari
amin
featur
may
suggest
could
act
similar
mechan
howev
oral
bioavail
gener
safe
human
thu
repurpos
drug
may
repres
fast
track
potenti
evalu
approv
feasibl
option
prevent
spread
mortal
associ
ebola
viru
larg
popul
sever
small
molecul
actual
test
small
number
human
activ
ebola
viru
exampl
press
favipiravir
undergo
phase
clinic
trial
us
influenza
approv
japan
shown
promis
efficaci
ebola
viru
mice
faviparavir
thought
act
inhibit
viral
rnadepend
rna
polymeras
select
demonstr
activ
number
virus
least
one
ebola
patient
sinc
recov
given
favipiravir
japan
offer
suppli
world
health
organ
second
experiment
drug
brincidofovir
phase
clinic
trial
treatment
cytomegaloviru
dna
virus
shown
efficaci
ebola
viru
vitro
anim
studi
ongo
brincidofovir
thought
mimic
cytidin
build
block
dna
therebi
inhibit
viral
dna
polymeras
mechan
action
ebola
viru
rna
viru
yet
unknown
brincidofovir
demonstr
safeti
human
given
least
two
ebola
viru
patient
one
dalla
one
nebraska
unfortun
dalla
patient
die
nebraska
patient
surviv
cours
earli
know
effect
molecul
progress
diseas
compound
prodrug
convert
activ
antivir
cidofovir
diphosph
brincidofovir
higher
oral
bioavail
intracellular
concentr
drug
increas
antivir
potenc
compound
appear
literatur
littl
publish
inform
beyond
earli
stage
drug
number
compound
identifi
activ
ebola
viru
summar
erik
de
clercq
mani
readi
human
use
may
present
attract
start
point
refin
futur
drug
discoveri
effort
exampl
novel
nucleosid
analog
demonstr
efficaci
mice
nonhuman
primat
ebola
viru
compound
target
viral
rna
polymeras
activ
induc
earli
termin
transcript
thu
block
replic
activ
ebola
viru
also
target
member
filoviru
famili
well
rna
viru
famili
potent
efficaci
effect
fasttrack
clinic
trial
human
recent
describ
expert
medicin
chemistri
analysi
nih
probe
compound
use
public
commerci
sourc
chemic
structur
issu
relat
type
analysi
like
chemistri
qualiti
probe
score
base
number
criteria
includ
literatur
relat
probe
potenti
chemic
reactiv
seri
machin
learn
model
also
comput
predict
score
identifi
painstak
manual
process
extern
valid
comparison
measur
druglik
filter
rule
suggest
compar
level
accuraci
care
analyz
similar
manner
small
molecul
activ
ebola
viru
identifi
literatur
search
chemist
cal
decis
compound
qualiti
summar
supplement
tabl
contrast
previou
work
score
compound
chemic
probe
current
aim
specif
treat
seriou
viral
diseas
phenotyp
readout
known
drug
clinic
use
reject
chemist
look
compound
look
interest
opinion
select
desir
analysi
potenti
problem
base
medicin
chemistri
experi
addit
manual
approach
appli
comput
filter
pan
assay
interfer
compound
pain
identifi
potenti
problemat
compound
structur
supplement
tabl
pain
analysi
enabl
use
mmd
mobil
app
base
approach
identifi
sever
molecul
appear
problemat
agre
medicin
chemistri
analysi
exampl
molecul
appear
fail
pain
filter
includ
rhodanin
compound
found
activ
numer
envelop
virus
found
screen
inhibitor
nipah
viru
entri
ic
vivo
steadi
state
plasma
concentr
could
maintain
therapeut
level
rhodanin
known
problemat
pain
compound
interestingli
amodiaquin
score
favor
pain
medicin
chemist
yet
success
antimalari
drug
addit
analyz
simpl
chemic
properti
calcul
collabor
drug
discoveri
cdd
vault
collabor
drug
discoveri
inc
use
chemaxon
toolkit
chemaxon
budapest
hungari
molecul
compar
medicin
chemistri
classif
tabl
mean
calcul
molecular
properti
valu
compound
compar
use
ttest
anova
jmp
v
sa
institut
cari
nc
signific
differ
note
logp
lipinski
rule
violat
desir
undesir
compound
although
one
molecul
skew
data
molecular
weight
tabl
remov
compound
lead
signific
differ
molecular
weight
number
hydrogen
bond
donor
heavi
atom
count
polar
surfac
area
addit
logp
lipinski
rule
violat
desir
compound
versu
undesir
compound
research
describ
small
molecul
inhibitor
ebola
viru
occur
disconnect
manner
effort
summar
total
medicin
chemistri
effort
date
think
research
learn
area
current
effort
improv
collabor
screen
area
tuberculosi
research
fund
bill
melinda
gate
foundat
european
commiss
enabl
tb
drug
acceler
medicin
tuberculosi
largescal
collabor
academia
research
institut
industri
collabor
promot
select
share
relat
data
secur
environ
collabor
use
cdd
vault
figur
central
avail
publicli
avail
data
compound
screen
activ
mycobacterium
tuberculosi
enabl
research
leverag
exist
literatur
alongsid
privat
data
knowledg
use
build
valid
comput
model
help
select
addit
compound
lead
optim
save
time
effort
organ
data
small
molecul
test
ebola
viru
similarli
central
databas
use
machin
learn
model
base
public
data
may
help
identifi
addit
compound
test
effort
may
also
prevent
duplic
effort
seen
screen
multipl
librari
fda
approv
compound
ebola
viru
order
catalyz
made
compound
supplement
tabl
freeli
avail
dataset
cdd
public
http
appcollaborativedrugcomregist
compound
represent
cdd
vault
access
via
text
compound
descriptor
supplement
tabl
batch
connect
tabl
format
mdl
format
structur
data
file
sdf
univers
read
chemistri
awar
softwar
abl
easili
retriev
chemic
structur
machin
retriev
form
consider
valu
identifi
compound
name
compani
code
number
per
se
allow
direct
access
chemic
structur
often
fail
entir
link
compound
identifi
chemistri
structur
compound
inchikey
great
advantag
searchabl
web
eg
via
googl
requir
lookup
tabl
eg
embl
unichem
get
back
chemic
structur
smile
inchi
represent
allow
direct
access
chemic
structur
compat
structur
search
public
chemistri
databas
well
proprietari
chemistri
ac
ca
scifind
databas
iupac
name
univers
use
name
chemic
compound
patent
softwar
exist
go
iupac
name
chemic
structur
compound
fda
approv
drug
diseas
activ
ebola
viru
vitro
vivo
may
repres
use
start
point
advantag
much
known
regard
adm
tox
properti
howev
may
ideal
opinion
medicin
chemist
bring
togeth
compound
describ
literatur
activ
ebola
viru
bodi
evid
may
convinc
studi
isol
addit
allow
us
consid
structur
featur
molecular
properti
may
provid
insight
target
mechan
action
unclear
whether
compound
might
also
activ
use
combin
therapi
current
standard
care
hiv
order
overcom
drug
resist
need
experiment
evalu
clearli
consider
distanc
fda
approv
drug
ebola
viru
analysi
illustr
alreadi
drug
shelf
potenti
repurpos
shorter
time
period
lower
cost
yet
appear
test
patient
ebola
viru
addit
least
molecul
opinion
experienc
medicin
chemist
possibl
optim
novel
compound
like
commerci
viabl
also
requir
consider
effort
assess
safeti
resourc
need
alloc
effort
administr
scientist
perhap
consid
medicin
chemistri
insight
provid
well
use
collabor
databas
share
molecul
activ
amongst
scientist
hope
effort
could
inspir
drug
discoveri
effort
around
small
molecul
illustr
level
interest
repurpos
effort
ebola
viru
follow
studi
identifi
upon
submiss
describ
addit
compound
well
alreadi
describ
herein
